Success in Comaneci-assist Coils Embolization Surveillance Study (SUCCESS)
Completed · NCT04518670
Conditions: Intracranial Aneurysm
At a glance
- Research payments reported, 2025
- $43,534
- U.S. investigators named
- 1
- Sites paid
- 6
- Planned or actual enrollment
- 90
About the trial
- Sponsor
- Rapid Medical
- Tested
- Comaneci Embolization Assist Device (device)
- Dates
- Started 2020-11-24; completion 2024-07-07
- Results posted
- Yes
The Comaneci Embolization Assist Device is indicated for use in the neurovasculature as a temporary endovascular device used to assist in the coil embolization of wide-necked intracranial aneurysms with a neck width ≤ 10 mm. A wide-necked intracranial aneurysm (IA) defines the neck width as ≥ 4 mm or a dome-to-neck ratio \< 2. The objective of the Postmarket Surveillance Plan is to assess safety and performance as used in postmarket clinical practice in the U.S.
From ClinicalTrials.gov, last updated 2026-01-21. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Rapid Medical Ltd reported $43,534 in research payments for this study in 2025 (10 payments).
Products named: Tigertriever 17 Revascularization Device, Comaneci 17
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- $16,500
- Semmes Murphey Foundation $10,788
- Thomas Jefferson Univeristy $5,746
- Houston Methodist Research Institute $3,500
- Southern California Permanente Medical Group $3,250
- South Alabama Medical Science Foundation $3,000
- University of Utah Hospital and Clinics, UT $750
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.